A Review of Patient-Reported Outcome Considerations in Oncologic Drugs Advisory Committee Meetings (2016-2021) Using a 20% sample of national Medicare data, we identified beneficiaries diagnosed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback